Urogen Pharma earnings were -$97.6M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest URGN earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$14.4M, down 39.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, URGN reported annual earnings of -$153.5M, with 21% growth.
On URGN's earnings call on Aug 5, 2026, Urogen Pharma (NASDAQ: URGN) reported Q2 2026 earnings per share (EPS) of -$0.28, up 73.33% year over year. Total URGN earnings for the quarter were -$14.35 million. In the same quarter last year, Urogen Pharma's earnings per share (EPS) was -$1.05.
As of the last Urogen Pharma earnings report, Urogen Pharma is currently losing money. Urogen Pharma's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$97.64 million, a 37% decrease year over year.
What was URGN's earnings growth in the past year?
As of Urogen Pharma's earnings date in Aug 5, 2026, Urogen Pharma's earnings has grown year over year. URGN earnings in the past year totalled -$97.64 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.